Brief: Captor Therapeutics Submits Application For Phase 1 Clinical Trial in Patients With Hepatocellular Carcinoma

Captor Therapeutics SA

23/08/2024 06:34

Aug 23 (Reuters) - Captor Therapeutics  CTXP.WA :
    * SAID ON THURSDAY IT HAS SUBMITTED APPLICATION FOR
PERMISSION TO
CONDUCT A FIRST IN HUMAN PHASE 1 CLINICAL TRIAL IN PATIENTS WITH
HEPATOCELLULAR CARCINOMA USING THE CT-01 COMPOUND 
    * THE APPLICATION WILL BE CONSIDERED BY EUROPEAN MEDICAL
AGENCY
(EMA)
    * THE MULTI-CENTER CLINICAL TRIAL WILL BE CONDUCTED AT
LEADING
EUROPEAN CENTERS FOR THE TREATMENT OF THIS CANCER IN SPAIN,
GERMANY AND FRANCE
    * THE PRIMARY OBJECTIVE OF THE STUDY IS TO EVALUATE THE
SAFETY AND
TOLERABILITY OF THE DRUG IN PATIENTS DIAGNOSED WITH PRIMARY
LIVER CANCER AND TO DETERMINE THE MAXIMUM TOLERATED DOSE AND/OR
RECOMMENDED DOSE FOR FURTHER CLINICAL PHASES, BOTH AS
MONOTHERAPY AND IN COMBINATION TREATMENT
    * IN ADDITION, THE STUDY WILL EVALUATE THE ANTI-TUMOR
ACTIVITY
USING RADIOLOGICAL IMAGING TECHNIQUES AND SERUM TUMOR MARKERS,
AS WELL AS THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE OF
THE DRUG CANDIDATE AFTER MONOTHERAPY AND IN COMBINATION
TREATMENT
    * THE ORGANIZATION OF THE STUDY WILL BE CARRIED OUT BY ICON
CLINICAL RESEARCH LIMITED 

        
 Source text for Workspace:  urn:newsml:reuters.com:*:nEM2Ly6pWa
 Further company coverage:  CTXP.WA  

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))